drugset
drugset / Trial / NCT02082457

Efficacy and Safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation

NCT02082457 ↗

Phase 2 Completed 273 enrolled SK Chemicals Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This trial is to investigate efficacy and safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation. The difference of responder rate between test group (10, 20 and 40mg) and placebo will be evaluated.

Timeline

Start
2013-12
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject RELENOPRIDE Small molecule 10 mg Oral
Subject RELENOPRIDE Small molecule 20 mg Oral
Subject RELENOPRIDE Small molecule 40 mg Oral

Indications

constipation disorder irritable bowel syndrome